aid: levicept
name: Levicept
description: 'Levicept Ltd is a UK-based clinical-stage biotechnology company headquartered
  at Innovation House, Discovery Park in Sandwich, Kent, developing LEVI-04, a fully
  human chimeric fusion protein combining the Fc fragment of human immunoglobulin G1
  with the p75 neurotrophin receptor (p75NTR) for the treatment of chronic pain. LEVI-04
  is a first-in-class neurotrophin-3 (NT-3) inhibitor designed to restore neurotrophin
  homeostasis and deliver analgesia without the use-limiting side effects — notably
  rapidly progressive osteoarthritis — seen with anti-NGF antibodies. The company completed
  a 510+ participant Phase II study in osteoarthritis of the knee (NCT05618782) that
  met all primary and secondary endpoints, published the results in The Lancet in March
  2026, and had its IND accepted by the US FDA in January 2026. Levicept is backed by
  Medicxi, Pfizer Ventures, Gilde Healthcare, Advent Life Sciences and Innovate UK.
  Levicept is a therapeutics developer, not a software vendor: it operates a WordPress
  corporate website and publishes no API, SDK, developer portal or machine-readable
  contract of any kind.'
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
image: https://levicept.com/wp-content/uploads/2024/04/logo-1.png
url: https://raw.githubusercontent.com/api-evangelist/levicept/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enrichment-pass
specificationVersion: '0.20'
created: '2026-08-25'
modified: '2026-08-25'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Therapeutics
- Clinical Trials
- Chronic Pain
- Osteoarthritis
- United Kingdom
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/levicept-domain-security.yml
- type: Website
  url: https://levicept.com/
- type: About
  url: https://levicept.com/about/
- type: Blog
  url: https://levicept.com/news/
- type: Support
  url: https://levicept.com/contact/
- type: PrivacyPolicy
  url: https://levicept.com/privacy-policy/
- type: Investors
  url: https://levicept.com/investors/
- type: Team
  url: https://levicept.com/team/
- type: LinkedIn
  url: https://www.linkedin.com/company/levicept-ltd/
x-enrichment:
  date: '2026-08-25'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: >-
    Levicept Ltd is a clinical-stage biopharma developing the LEVI-04 biologic for
    osteoarthritis pain; its entire web presence is an eleven-page WordPress
    corporate site (about/science/trials/team/investors/news/contact) with no
    developer, API or integration page, and STEP 0b contract discovery on both
    levicept.com and www.levicept.com returned 404 for every OpenAPI, GraphQL,
    MCP, agent-card and /.well-known path.
  evidence:
  - url: https://levicept.com/
    status: 200
  - url: https://levicept.com/developers
    status: 404
  - url: https://levicept.com/openapi.json
    status: 404
  - url: https://levicept.com/graphql
    status: 404
  - url: https://levicept.com/.well-known/agent-card.json
    status: 404
  - url: https://api.github.com/orgs/levicept
    status: 404
  checked: '2026-08-25'